On March 30, 2026, Infant Bacterial Therapeutics AB (publ) published a notice of the Annual General Meeting to be held on May 7, 2026. The following is...
2026-03-30 14:30
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
The Annual Report including Corporate Governance Report for 2025 is available on IBT´s website, www.ibtherapeutics.com under the section "Investors...
2026-03-03 07:00
Infant Bacterial Therapeutics (IBT) publishes results from ”The Connection Study” in Pediatric Research
IBT is pleased to announce that results from its pivotal Phase III trial, with IBP-9414 in very low birth weight infants “The Connection Study&rdquo...
2026-02-06 07:30
Infant Bacterial Therapeutics AB (publ) Year-end-report January 1 – December 31, 2025
Message from CEO IBT's plan to apply for marketing approval in the US through a so-called accelerated application remains unchanged. The development program...
2025-12-11 18:05
Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product
Infant Bacterial Therapeutics AB (IBT) whose mission is to develop and commercialize pharmaceuticals for diseases affecting premature babies and BioConnection...
Following today's meeting with the FDA concerning IBT's live biotherapeutic product, IBT has decided to pursue an accelerated approval pathway for IBP-9414...
2025-11-20 16:42
Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for production of drug substance
Infant Bacterial Therapeutics AB (IBT) and Recipharm Advanced Bio, a segment of Recipharm and a leading Contract Development and Manufacturing Organisation...
2025-11-13 07:30
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2025
Message from CEO The risk of death decreased by 27% for children who received our drug candidate IBP-9414 compared to placebo in our Phase 3 study. It...
2025-10-20 10:35
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026
The 2025 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...